| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/20/1997 | WO1997005871A1 Nitric oxide synthase (nos) inhibitors |
| 02/20/1997 | WO1997005865A1 C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen |
| 02/20/1997 | WO1997005864A2 Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral drugs |
| 02/20/1997 | WO1997005862A2 Use of basic amino acids and derivatives for lowering ceramide levels |
| 02/20/1997 | WO1997005859A2 Use of alicyclic diamines as immunomodulators |
| 02/20/1997 | WO1997005780A1 Regulation of alzheimer's disease related proteins and uses thereof |
| 02/20/1997 | WO1997005771A2 Lysosomal proteins produced in the milk of transgenic animals |
| 02/20/1997 | CA2229098A1 C-proteinase inhibitors for the treatment of disorders related to the overproduction of collagen |
| 02/20/1997 | CA2229074A1 Nitric oxide synthase (nos) inhibitors |
| 02/20/1997 | CA2229044A1 Recombinant c-proteinase and processes, methods and uses thereof |
| 02/20/1997 | CA2228689A1 Use of alicyclic diamines as immunomodulators |
| 02/20/1997 | CA2228650A1 Use of betaglycan to reduce scarring |
| 02/20/1997 | CA2228620A1 Treatment of ocular inflammatory conditions with interleukin-10 |
| 02/20/1997 | CA2228314A1 Use of pde inhibitors in the manufacture of a medicament for the treatment of bladder diseases |
| 02/20/1997 | CA2228286A1 Substituted 1-indolylpropyl-4-phenethylpiperazine derivatives |
| 02/20/1997 | CA2228136A1 2-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| 02/20/1997 | CA2228050A1 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| 02/20/1997 | CA2225647A1 Regulation of alzheimer's disease related proteins and uses thereof |
| 02/20/1997 | CA2213773A1 Imidazopyridine derivatives |
| 02/19/1997 | EP0758650A1 Endothelin receptor antagonists |
| 02/19/1997 | EP0758648A1 Substituted 4H-pyrans with a modulating effect on calcium channels |
| 02/19/1997 | EP0758644A1 Sulfonyl- or sulfinyl-benzoyl-guanidine derivatives |
| 02/19/1997 | EP0758452A1 Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same |
| 02/19/1997 | EP0758330A1 Biphenylcarboxamides useful as 5-ht1d antagonists |
| 02/19/1997 | EP0758328A1 Anti-cancer compounds containing cyclopentaquinazoline ring |
| 02/19/1997 | EP0758312A1 Substituted fused and bridged bicyclic compounds as therapeutic agents |
| 02/19/1997 | EP0758241A1 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration |
| 02/19/1997 | EP0758238A1 Spiro-substituted azacycles as neurokinin-3 antagonists |
| 02/19/1997 | EP0758234A1 Method and composition for treating renal disease and failure |
| 02/19/1997 | EP0491878B1 Compositions for the inhibition of protein hormone formation and uses thereof |
| 02/19/1997 | CN1143386A Transforming growth factor alpha-H1 |
| 02/19/1997 | CN1143372A Haemopoietic manuration factor |
| 02/19/1997 | CN1143371A Corpuscles of stannius protein, stanniocalcin |
| 02/19/1997 | CN1143365A Phenyl-heterocycles as COX-2 inhibitors |
| 02/19/1997 | CN1143358A Benzamide analogs, useful as parp (ADP-ribosyltransferase, ADRPT) DNA repair enzyme inhibitors |
| 02/19/1997 | CN1143324A Novel pharmaceutical composition for skin diseases |
| 02/19/1997 | CN1143323A Bicyclic fibrinogen antagonists |
| 02/19/1997 | CN1143321A Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
| 02/19/1997 | CN1143319A Compound and methods for treatment of cardiovascular, inflammatory and immune disorders |
| 02/19/1997 | CN1143084A Anti-oxidant grafted polysaccharide and its use |
| 02/19/1997 | CN1142945A Medcine for curing cerebrovascular disturbance with psychonosema |
| 02/19/1997 | CN1034077C Preparation of new pyrido|2,3-f¨|1,4¨ thiazepines |
| 02/19/1997 | CN1034072C Preparing method for tetrahydrocarbazole derivative |
| 02/18/1997 | US5604261 Having hydroxyl/alkoxyl group ortho to amide group on phenyl ring; high melatonin receptor affinity |
| 02/18/1997 | US5604260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 |
| 02/18/1997 | US5604259 Adminstering for the treatment of osteoporosis |
| 02/18/1997 | US5604257 Useful as an osteogenetic accelerator |
| 02/18/1997 | US5604252 Substance p antagonist |
| 02/18/1997 | US5604248 Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
| 02/18/1997 | US5604247 Chromone Derivatives |
| 02/18/1997 | US5604245 Use of 4-amino-1-(2-pyridyl)piperidines for the preparation of a medicament for the treatment of conditions deriving from disorders of the serotoninergic systems mediated by 5-HT3 receptors |
| 02/18/1997 | US5604239 Imidazopyridines as serotonergic 5-HT3 antagonists |
| 02/18/1997 | US5604237 Improve or increase efficacy of antitumor agent, increase or restore sensitivity of tumor to antitumor agent, reverse or reduce resistance of tumor to antitumor agent |
| 02/18/1997 | US5604236 Beta-carboline thromboxane synthase inhibitors |
| 02/18/1997 | US5604221 Treating congestive heart failure, irritable bowel syndrome |
| 02/18/1997 | US5604215 Sulfonated oestrone or dehydroepiandrosterone and derivatives; anti breast cancer agent |
| 02/18/1997 | US5604116 Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods |
| 02/18/1997 | US5604094 Receptor-type phosphotyrosine phosphatase-β |
| 02/18/1997 | US5603957 Microcapsules for the controlled release of acetylsalicyclic acid in the gastrointestinal environment |
| 02/18/1997 | US5603943 Physiologically active substance homogeneously dispersed in and adsorbed on polyvalent metal carrier of specified particle size |
| 02/17/1997 | CA2183307A1 Endothelin receptor antagonists |
| 02/15/1997 | CA2183048A1 Substituted 4h-pyrans |
| 02/13/1997 | WO1997005285A2 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | WO1997005279A1 Methods of predicting the outcome of infection |
| 02/13/1997 | WO1997005254A1 CYTIDINE DEAMINASE cDNA AS A POSITIVE SELECTABLE MARKER FOR GENE TRANSFER, GENE THERAPY AND PROTEIN SYNTHESIS |
| 02/13/1997 | WO1997005244A1 Mocarhagin, a cobra venom protease, and therapeutic uses thereof |
| 02/13/1997 | WO1997005241A2 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | WO1997005168A1 The h-y antigen |
| 02/13/1997 | WO1997005155A1 Photolabile 8-substituted cyclic nucleotide esters, methods of preparing them and their use |
| 02/13/1997 | WO1997005105A1 N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
| 02/13/1997 | WO1997004806A1 Remedy for neurological disorders |
| 02/13/1997 | WO1997004781A1 Endothelin receptor antagonists |
| 02/13/1997 | WO1997004779A1 Quinolones and their therapeutic use |
| 02/13/1997 | WO1997004773A1 Endothelin receptor antagonists |
| 02/13/1997 | WO1997004772A1 Endothelin receptor antagonists |
| 02/13/1997 | WO1997004771A1 Benzimidazole compounds |
| 02/13/1997 | WO1997004768A1 Non-ionic surfactant vesicles as therapeutic agent |
| 02/13/1997 | WO1997004765A1 INHIBITION OF CoA-INDEPENDENT TRANSACYLASE AND APOPTOSIS |
| 02/13/1997 | WO1997004760A1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 02/13/1997 | WO1996035774A3 Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/13/1997 | WO1996034969A3 Gene therapy using replication competent targeted adenoviral vectors |
| 02/13/1997 | WO1996002240A3 Use of inhibitors of human s-cd23 |
| 02/13/1997 | DE19529612A1 Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate Sulfonyl or sulfinyl derivatives benzoylguanidine |
| 02/13/1997 | DE19529223A1 Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau Use of plasminogen activators to the local bone formation |
| 02/13/1997 | DE19529102A1 Verwendung von PDE-Inhibitoren bei der Behandlung von Harnblasenerkrankungen Use of PDE inhibitors in the treatment of urinary bladder diseases |
| 02/13/1997 | CA2228378A1 Cytidine deaminase cdna as a positive selectable marker for gene transfer, gene therapy and protein synthesis |
| 02/13/1997 | CA2228298A1 Non-ionic surfactant vesicles as therapeutic agent |
| 02/13/1997 | CA2228296A1 Endothelin receptor antagonists |
| 02/13/1997 | CA2228293A1 Endothelin receptor antagonists |
| 02/13/1997 | CA2227972A1 Mocarhagin, a cobra venom protease and therapeutic uses thereof |
| 02/13/1997 | CA2227769A1 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | CA2227694A1 Methods and compositions for identifying morphogen analogs |
| 02/13/1997 | CA2225552A1 Quinolones and their therapeutic use |
| 02/13/1997 | CA2225465A1 Benzimidazole compounds |
| 02/13/1997 | CA2224894A1 The h-y antigen |
| 02/13/1997 | CA2224293A1 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity |
| 02/12/1997 | EP0758021A2 Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof |
| 02/12/1997 | EP0757982A1 Biphenylic compounds, process for their preparations and intermediates for this process, their use as 5-alpha-reductase inhibitors and pharmaceutical compositions containing them |
| 02/12/1997 | EP0757718A1 Methods of use of uncoated gel particles |
| 02/12/1997 | EP0757716A1 Dna encoding bradykinin b 1? receptor |